 Genprex, Inc. NASDAQ:GNPX has announced that the Safety Review Committee SRC has approved continuation to the third and final cohort in the dose escalation Phase 1 portion of the Acclaim-1 Phase 12 clinical trial of REQORSA in combination with Tagrisso osimertinib to treat late-stage non-small cell lung cancer NSCLC. The SRC is comprised of three physicians who are principal investigators in the trial. 